Form 4: Enanta CMO Forfeits Shares for Tax Withholding

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, reported a future forfeiture of 2,217 common shares to cover tax obligations from a restricted stock unit award.

Summary

• Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals Inc. (ENTA), reported a transaction.
• On August 8, 2025, 2,217 shares of ENTA common stock were forfeited.
• The forfeiture was to cover withholding taxes due to the settlement of a restricted stock unit (RSU) award.
• The RSU award was originally granted on August 8, 2022.
• The price per share for the forfeited stock was $6.99.
• Following this transaction, Mr. Rottinghaus beneficially owns 22,590 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine and expected event related to executive compensation (RSU vesting and tax withholding), which is neutral in terms of company performance or outlook.

Positives

• The transaction indicates the vesting and settlement of a restricted stock unit award, which is a positive for the executive as it represents compensation becoming liquid.

Negatives

• The forfeiture of shares, while standard for tax withholding, reduces the executive's direct ownership.

Future Outlook

This filing reports a future transaction related to the vesting of previously granted restricted stock units, indicating an upcoming compensation event for the Chief Medical Officer.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing, which is typical for this document type.

Industry Context

This routine insider transaction, involving the forfeiture of shares for tax withholding upon RSU vesting, is a common compensation event in the biotechnology and pharmaceutical industries. It does not reflect broader industry trends but rather the standard operation of executive compensation plans.

Comparison to Industry Standards

• The forfeiture of shares to cover tax obligations upon the vesting of restricted stock units is a standard practice across industries, including biotechnology. This mechanism is widely used in executive compensation plans to manage the tax implications of equity awards. No specific comparable companies or projects are relevant for this type of routine compensation disclosure.

Stakeholder Impact

• Minimal direct impact on shareholders, as this is a routine executive compensation event.
• Positive for the Chief Medical Officer, as it represents the settlement of a portion of their equity compensation.

Next Steps

• No specific future actions or milestones are mentioned beyond the reported future transaction date.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, SEC filing, insider transaction, restricted stock units, RSU, tax withholding, Chief Medical Officer, Scott T. Rottinghaus